- Home
- BANC vs AKRO Comparison
BANC vs AKRO Comparison
Compare BANC & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANC
- AKRO
- Stock Information
- Founded
- BANC 1941
- AKRO 2017
- Country
- BANC United States
- AKRO United States
- Employees
- BANC N/A
- AKRO N/A
- Industry
- BANC Major Banks
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- BANC Finance
- AKRO Health Care
- Exchange
- BANC Nasdaq
- AKRO Nasdaq
- Market Cap
- BANC 2.5B
- AKRO 2.1B
- IPO Year
- BANC N/A
- AKRO 2019
- Fundamental
- Price
- BANC $15.81
- AKRO $31.59
- Analyst Decision
- BANC Buy
- AKRO Strong Buy
- Analyst Count
- BANC 11
- AKRO 7
- Target Price
- BANC $17.27
- AKRO $43.20
- AVG Volume (30 Days)
- BANC 2.2M
- AKRO 441.5K
- Earning Date
- BANC 10-22-2024
- AKRO 11-11-2024
- Dividend Yield
- BANC 2.54%
- AKRO N/A
- EPS Growth
- BANC N/A
- AKRO N/A
- EPS
- BANC N/A
- AKRO N/A
- Revenue
- BANC $412,570,000.00
- AKRO N/A
- Revenue This Year
- BANC N/A
- AKRO N/A
- Revenue Next Year
- BANC $9.72
- AKRO N/A
- P/E Ratio
- BANC N/A
- AKRO N/A
- Revenue Growth
- BANC N/A
- AKRO N/A
- 52 Week Low
- BANC $10.81
- AKRO $11.36
- 52 Week High
- BANC $15.86
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- BANC 65.16
- AKRO 66.34
- Support Level
- BANC $15.20
- AKRO $29.34
- Resistance Level
- BANC $15.69
- AKRO $32.15
- Average True Range (ATR)
- BANC 0.43
- AKRO 1.26
- MACD
- BANC 0.10
- AKRO 0.10
- Stochastic Oscillator
- BANC 97.95
- AKRO 99.74
About BANC Banc of California Inc.
Banc of California Inc is a financial holding company. It offers banking and financial services. The company's services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.